Rheumatoid Arthritis News and Research RSS Feed - Rheumatoid Arthritis News and Research

Rheumatoid arthritis (RA) is a chronic disease of the joints that can cause a disabling degree of pain and significantly interfere with an individual’s day-to-day living.

RA is an autoimmune disease, meaning the immune system, which is usually geared up to fight infection, attacks the lining of the joints, causing them to swell and become stiff and painful. Eventually, the joint itself can become damaged as well as the cartilage and surrounding bone. Any joint can be affected but most commonly the illness involves the hands, feet and wrists.

The condition is more common among women than men and usually affects people between the ages of 40 and 70, although it can affect people of any age.

Symptoms range from mild to severe and can flare-up suddenly and unpredictably, making the condition very difficult to live with.

The exact cause of rheumatoid arthritis is not yet fully understood but some research suggests that viruses and bacteria may be involved. RA cannot be cured but early diagnosis and treatment can help to manage symptoms and prevent disability.
Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed. [More]
TSRI scientists show how to target weak spots of Marburg virus with future treatments

TSRI scientists show how to target weak spots of Marburg virus with future treatments

Marburg virus is Ebola's deadly cousin. The virus is up to 90 percent lethal—and doctors are desperate for tools to fight it. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis. [More]

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. [More]
Indiana University study reveals connection between mussels and muscles

Indiana University study reveals connection between mussels and muscles

An Indiana University study has revealed that there may be a greater connection between mussels and muscles than previously thought. [More]
Two Glenmark manufacturing facilities in India win Greentech Environment Gold Award - 2015

Two Glenmark manufacturing facilities in India win Greentech Environment Gold Award - 2015

Two manufacturing facilities of Glenmark located in Goa and Nashik bagged the prestigious 'Greentech Environment Gold Award - 2015' for Excellence in Environment Management at a ceremony in Kolkata recently. Greentech Environment Awards are presented ever year to companies/units in India demonstrating the highest level of commitment to Environmental Management across different sectors. [More]

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference. [More]
Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center. [More]
TSRI scientists develop new drug candidate against HIV

TSRI scientists develop new drug candidate against HIV

In a remarkable new advance against the virus that causes AIDS, scientists from the Jupiter, Florida campus of The Scripps Research Institute have announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine. [More]
Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease

Postmenopausal women susceptible to bone fractures may be at increased risk for gum disease

Postmenopausal women susceptible to bone fractures may also be a higher risk for gum disease, according to researchers at Case Western Reserve University School of Dental Medicine and Case/Cleveland Clinic Postmenopausal Health Collaboration. [More]
Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases. [More]
Study shows link between autoimmune diseases and gene regulatory elements

Study shows link between autoimmune diseases and gene regulatory elements

Investigators with the National Institutes of Health have discovered the genomic switches of a blood cell key to regulating the human immune system. [More]
USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis. [More]
Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. [More]
Techimmuna may help diagnose rheumatoid arthritis

Techimmuna may help diagnose rheumatoid arthritis

NCBJ POLATOM Radioisotope Centre has just introduced a new product to the nuclear medicine preparations market. Techimmuna will help to diagnose various cases of inflammation, in particular rheumatoid arthritis. [More]
PAH survival unaffected by rheumatoid arthritis origin

PAH survival unaffected by rheumatoid arthritis origin

Patients with rheumatoid arthritis-associated pulmonary arterial hypertension have comparable survival to those with idiopathic pulmonary arterial hypertension, researchers report. [More]
Researchers develop new method for preventing destructive activity of osteoclasts

Researchers develop new method for preventing destructive activity of osteoclasts

Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability. [More]
Mercury associated with autoimmunity among women of childbearing age

Mercury associated with autoimmunity among women of childbearing age

One of the greatest risk factors for autoimmunity among women of childbearing age may be associated with exposure to mercury such as through seafood, a new University of Michigan study says. [More]
Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. [More]